Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Lymphoma, T-Cell, Peripheral 15Lymphoma 14Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Large-Cell, Anaplastic 5Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Leukemia 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplasms 3Mycosis Fungoides 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lung Neoplasms 3Hodgkin Disease 3Hematologic Neoplasms 3Congenital Abnormalities 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sezary Syndrome 2

Interventions

Magnetic Resonance Spectroscopy 4Iodine-131 4Sunitinib 3dabrafenib 2Trastuzumab 2Thyrotropin Alfa 2Thyroidectomy 2Surgical Procedures, Operative 2Gefitinib 2Fluorodeoxyglucose F18 2Bortezomib 2AZD 6244 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1trametinib 1tipifarnib 1tanespimycin 1sargramostim 1romidepsin 1pralsetinib 1pembrolizumab 1pazopanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1delta 24-sterol reductase 1copanlisib 1cediranib 1aldesleukin 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid Cancer, Papillary × romidepsin × Clear all
NCT00098813 2014-05-28

Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine

National Cancer Institute (NCI)

Phase 2 Completed
20 enrolled 7 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡